Commonwealth Equity Services LLC cut its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 25.5% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 41,105 shares of the biotechnology company’s stock after selling 14,065 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Arrowhead Pharmaceuticals were worth $2,690,000 as of its most recent SEC filing.
Other hedge funds have also recently bought and sold shares of the company. Carolina Wealth Advisors LLC lifted its stake in Arrowhead Pharmaceuticals by 80.6% in the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 154 shares during the last quarter. Optiver Holding B.V. grew its position in shares of Arrowhead Pharmaceuticals by 83.8% in the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 186 shares during the period. Versant Capital Management Inc grew its position in shares of Arrowhead Pharmaceuticals by 285.1% in the 2nd quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 248 shares during the period. QRG Capital Management Inc. increased its stake in shares of Arrowhead Pharmaceuticals by 7.1% during the 2nd quarter. QRG Capital Management Inc. now owns 4,810 shares of the biotechnology company’s stock worth $392,000 after purchasing an additional 317 shares during the last quarter. Finally, Pine Valley Investments Ltd Liability Co increased its stake in shares of Arrowhead Pharmaceuticals by 1.8% during the 1st quarter. Pine Valley Investments Ltd Liability Co now owns 18,814 shares of the biotechnology company’s stock worth $1,180,000 after purchasing an additional 335 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
A number of research firms have recently issued reports on ARWR. Chardan Capital reaffirmed a “buy” rating and issued a $115.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Thursday, October 15th. Stifel Nicolaus decreased their target price on Arrowhead Pharmaceuticals from $104.00 to $96.00 and set a “buy” rating on the stock in a report on Friday, November 13th. The Goldman Sachs Group assumed coverage on Arrowhead Pharmaceuticals in a report on Thursday, September 24th. They set a “neutral” rating and a $74.00 target price on the stock. Wall Street Zen cut Arrowhead Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 14th. Finally, UBS Group started coverage on Arrowhead Pharmaceuticals in a report on Thursday, October 15th. They set a “buy” rating and a $109.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $98.71.
Check Out Our Latest Research Report on ARWR
Arrowhead Pharmaceuticals Price Performance
Shares of NASDAQ:ARWR opened at $43.65 on Friday. The firm has a 50 day moving average of $60.06 and a 200-day moving average of $70.49. The stock has a market capitalization of $6.17 billion, a PE ratio of -8.54 and a beta of 1.34. The company has a current ratio of 4.14, a quick ratio of 4.11 and a debt-to-equity ratio of 16.61. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $37.06 and a 12 month high of $95.49.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that develops medicines using RNA interference (RNAi), a biological process that can reduce the production of specific proteins by silencing the genes that encode them. Its proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi treatments to targeted tissues. The company’s research and development programs address a range of conditions, including liver, cardiometabolic, pulmonary and neurological diseases. Its work centers on investigational medicines and drug-development partnerships.
Recommended Stories
- Five stocks we like better than Arrowhead Pharmaceuticals
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report).
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
